FeesSafety
Pluang+

DiaMedica advances DM199 drug trials with key stroke and preeclampsia updates due by 2027

Analyst Insights
16 Nov 2026, 07:24 WIB
Seeking Alpha
View Source
Bullish
DiaMedica advances DM199 drug trials with key stroke and preeclampsia updates due by 2027

DiaMedica Therapeutics is progressing its lead drug DM199 in phase 2/3 trials for Acute Ischemic Stroke, with a significant interim analysis expected in Q1 2027. The company also plans a November 2026 update on fetal growth restriction data and has secured trial authorizations for preeclampsia in Europe and Canada, pending U.S. trial initiation after toxicity data review. These developments could impact the drug's future approval and market potential.

DiaMedica Therapeutics updates are provided here with Pluang's Health sector data for context. As of Nov 16, 2026 12:41 WIB, 48 of 150 Health-sector US stocks rose while 99 fell. Notable movers include Moderna (MRNA) at USD 216.60, down 12.90%, Aveanna Healthcare (AVAH) at USD 11.50, down 12.15%, and Citius Pharmaceuticals (CTXR) at USD 0.54, up 11.34%.

More News

Chinese beauty innovation shines at 2026 INPD in Paris with OSM winning top RMB 1M award

Chinese beauty innovation shines at 2026 INPD in Paris with OSM winning top RMB 1M award

The 2026 International Cosmetics Innovation Summit and Awards (INPD) was held in Paris, showcasing Chinese beauty companies' innovations under the theme "REGENERATIONS." Sixteen Chinese brands received awards for breakthroughs in ingredients, formula...

Bullish
1 hour ago
OrdoAI launches Ordo Brand AI tool to streamline global marketing with creator partnerships, public release in Q1 2027.

OrdoAI launches Ordo Brand AI tool to streamline global marketing with creator partnerships, public release in Q1 2027.

OrdoAI, a company specializing in AI-driven global marketing, is expanding into AI product development with its first AI agent, Ordo Brand. This tool helps brands and agencies manage creator partnerships across markets by simplifying discovery, outre...

Others
Bullish
1 hour ago
Avoid iShares Broad USD High Yield Corporate Bond ETF due to US macro risks and credit spread sensitivity.

Avoid iShares Broad USD High Yield Corporate Bond ETF due to US macro risks and credit spread sensitivity.

The Valkyrie Trading Society advises against investing in the iShares Broad USD High Yield Corporate Bond ETF (USHY) because of its significant exposure to US macroeconomic risks and credit spreads. With a duration of 3.13 years, USHY is sensitive to...

Market News
Bearish
5 hours ago
Bitcoin liquidation clusters identified near $66,000 and $63,000 price levels signal potential market shifts.

Bitcoin liquidation clusters identified near $66,000 and $63,000 price levels signal potential market shifts.

A Bitcoin liquidation map dated Nov. 16 highlights significant short-side liquidation intensity at $66,000 and long-side intensity at $63,000 across major centralized exchanges. These levels indicate potential price points where market reactions coul...

Technical Signals
Neutral
5 hours ago
Sanmina shares trade near 10x earnings with growth driven by cloud and AI, despite some risks.

Sanmina shares trade near 10x earnings with growth driven by cloud and AI, despite some risks.

Sanmina's fiscal 2027 guidance projects $17.5–$19.5 billion in sales and about $16.50 in earnings per share, with shares currently trading near 10 times earnings after adjusting for stock compensation. Growth is expected to be driven by cloud and AI ...

Analyst Insights
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App